Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CPH
- Development stage
- Preclinical
- Lead developer
- Merck
- Modality
- Small Molecules, Peptides, Hydrogel Systems → Drug Delivery Systems
- Administration
- Oral, Intravenous, Intramuscular
01
Overview
CPH is a non-specific abbreviation used in clinical and scientific literature to refer to several distinct substances. Most commonly in a pharmaceutical context, it refers to **cyproheptadine**, a first-generation antihistamine and serotonin antagonist used for allergic conditions, appetite stimulation, and the management of serotonin syndrome; it is also being investigated for motor recovery in chronic spinal cord injury. Additionally, CPH refers to **chicken protein hydrolysate**, a dietary supplement composed of bioactive peptides studied for its potential to reduce abdominal obesity and improve metabolic health. In agricultural and oncological research, CPH denotes **cocoa pod husk**, a natural extract rich in polyphenols being evaluated for anticancer activity against hepatocellular carcinoma. Finally, CPHs is a frequent shorthand for the **cephalosporin** class of beta-lactam antibiotics.
- Brand names
- Periactin
- Other names
- cyproheptadinechicken protein hydrolysatecocoa pod huskcephalosporins
02
Targets
HTR2A (Serotonin receptor 5-HT2A)HTR2B (5-Hydroxytryptamine Receptor 2B)HTR2C (5-hydroxytryptamine 2C receptor)HRH1 (Histamine H1 Receptor)mAChR (Muscarinic acetylcholine receptors)ACE (Angiotensin Converting Enzyme)DPP-4 (Dipeptidyl Peptidase-IV)EGFR (Epidermal growth factor receptor)PBP (Penicillin-binding protein family)PIK3CA (Phosphoinositide 3-kinase alpha)SRC (Proto-oncogene tyrosine-protein kinase Src)
Beyond the preview
Go deeper on CPH.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CPH.